PL1923073T3 - Leczenie kombinacyjne z inhibitorem PDE-5 - Google Patents

Leczenie kombinacyjne z inhibitorem PDE-5

Info

Publication number
PL1923073T3
PL1923073T3 PL06025229T PL06025229T PL1923073T3 PL 1923073 T3 PL1923073 T3 PL 1923073T3 PL 06025229 T PL06025229 T PL 06025229T PL 06025229 T PL06025229 T PL 06025229T PL 1923073 T3 PL1923073 T3 PL 1923073T3
Authority
PL
Poland
Prior art keywords
inhibitor
portal hypertension
prevent
portal
treat
Prior art date
Application number
PL06025229T
Other languages
English (en)
Inventor
Wolfgang Kreisel
Deibert Peter
Original Assignee
Univ Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Freiburg filed Critical Univ Freiburg
Publication of PL1923073T3 publication Critical patent/PL1923073T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL06025229T 2003-06-06 2004-06-03 Leczenie kombinacyjne z inhibitorem PDE-5 PL1923073T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10325813A DE10325813B4 (de) 2003-06-06 2003-06-06 Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP04739573A EP1635838B1 (de) 2003-06-06 2004-06-03 Phosphodiesterase-5-inhibitoren zur prophylaxe und/oder therapie der portalen hypertonie
EP06025229A EP1923073B1 (de) 2003-06-06 2004-06-03 Kombinationsmedikation mit PDE-5-Inhibitor

Publications (1)

Publication Number Publication Date
PL1923073T3 true PL1923073T3 (pl) 2012-02-29

Family

ID=33494881

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06025229T PL1923073T3 (pl) 2003-06-06 2004-06-03 Leczenie kombinacyjne z inhibitorem PDE-5
PL04739573T PL1635838T3 (pl) 2003-06-06 2004-06-03 Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04739573T PL1635838T3 (pl) 2003-06-06 2004-06-03 Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego

Country Status (14)

Country Link
US (1) US9278097B2 (pl)
EP (2) EP1635838B1 (pl)
JP (3) JP4557970B2 (pl)
KR (2) KR101176110B1 (pl)
CN (1) CN1871010B (pl)
AT (2) ATE361074T1 (pl)
CY (2) CY1107707T1 (pl)
DE (2) DE10325813B4 (pl)
DK (2) DK1923073T3 (pl)
ES (2) ES2287740T3 (pl)
PL (2) PL1923073T3 (pl)
PT (2) PT1635838E (pl)
SI (2) SI1923073T1 (pl)
WO (1) WO2004108062A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314044B2 (en) * 2001-05-09 2006-09-21 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1888074B1 (en) 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
US8512258B2 (en) * 2005-11-11 2013-08-20 Exalenz Bioscience Ltd. Breath test device and method
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
WO2014088326A1 (ko) 2012-12-04 2014-06-12 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US11576609B2 (en) 2017-06-30 2023-02-14 Georgia State University Research Foundation, Inc. Noninvasive methods for detecting liver fibrosis
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
CN110811593A (zh) * 2019-11-07 2020-02-21 天津中医药大学第二附属医院 一种高血压中医证型采取肝血流动力学特点的判别方法
KR20240117491A (ko) 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2882843B2 (ja) 1990-03-28 1999-04-12 日本化薬株式会社 門脈圧亢進症改善剤
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5973011A (en) * 1994-03-30 1999-10-26 Isis Pharma Gmbh Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
DE19961302A1 (de) * 1999-12-18 2001-06-21 Dresden Arzneimittel Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
KR20010101603A (ko) 1999-01-20 2001-11-14 노왈드 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도
AU3210500A (en) * 1999-01-22 2000-08-07 Selectus Pharmaceuticals, Inc. Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
DE10004858A1 (de) 2000-02-03 2001-08-16 Schering Ag Verwendung von Proteinkinase-Inhibitor-alpha
US20020103117A1 (en) * 2000-02-03 2002-08-01 Ralph Knoell Use of protein kinase-inhibitor-alpha
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
EP1313478A2 (en) 2000-08-30 2003-05-28 Lilly Icos LLC Method for treatment of migraine using pde5 inhibitors
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
JP2002201128A (ja) 2000-10-25 2002-07-16 Takeda Chem Ind Ltd 門脈圧亢進症予防・治療剤
AU2002210925A1 (en) * 2000-10-25 2002-05-06 Takeda Chemical Industries Ltd. Preventives/remedies for portal hypertension
WO2002060449A2 (de) * 2001-01-31 2002-08-08 Merck Patent Gmbh Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate
CZ20032350A3 (en) 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
EP1355651A2 (en) * 2001-02-02 2003-10-29 Pfizer Limited Treatment of diabetes mellitus using vardenafil
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
LV12979B (en) 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition

Also Published As

Publication number Publication date
ES2287740T3 (es) 2007-12-16
DK1923073T3 (da) 2011-10-17
KR20120024807A (ko) 2012-03-14
DK1635838T3 (da) 2007-09-10
ATE361074T1 (de) 2007-05-15
CN1871010B (zh) 2010-05-26
EP1923073A3 (de) 2008-07-09
CY1107707T1 (el) 2013-04-18
EP1923073A2 (de) 2008-05-21
US9278097B2 (en) 2016-03-08
WO2004108062A2 (de) 2004-12-16
EP1923073B1 (de) 2011-09-21
JP2006527177A (ja) 2006-11-30
KR20060031614A (ko) 2006-04-12
JP4557970B2 (ja) 2010-10-06
SI1635838T1 (sl) 2007-10-31
JP2010195821A (ja) 2010-09-09
DE502004003694D1 (de) 2007-06-14
EP1635838A2 (de) 2006-03-22
CN1871010A (zh) 2006-11-29
PT1635838E (pt) 2007-08-10
ES2374085T3 (es) 2012-02-13
DE10325813B4 (de) 2007-12-20
KR101233828B1 (ko) 2013-02-14
ATE525074T1 (de) 2011-10-15
US20070004744A1 (en) 2007-01-04
CY1111918T1 (el) 2015-11-04
DE10325813A1 (de) 2005-01-05
SI1923073T1 (sl) 2011-11-30
PL1635838T3 (pl) 2007-09-28
KR101176110B1 (ko) 2012-08-22
WO2004108062A3 (de) 2005-03-10
PT1923073E (pt) 2011-10-04
JP5757677B2 (ja) 2015-07-29
JP5631053B2 (ja) 2014-11-26
EP1635838B1 (de) 2007-05-02
JP2009280602A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
CY1111918T1 (el) Συνδυασμενη φαρμακευτικη αγωγη με αναστολεα της φωσφωδιεστερασης-5
HK1048250A1 (zh) 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
EP1500403A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
WO2003035009A3 (en) Treatment of acute myeloid leukemia with indolinone compounds
NO20006484D0 (no) Pro-legemidler av dipeptidyl peptidase IV-inhibitorer
EP1541551A8 (en) 2-cyano-4-fluoropyrrolidine derivative or its salt
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
NO20063572L (no) Kinazolinditosylatsalt forbindelser
WO2000028980A3 (en) Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
EP1389988A4 (en) CATHETER SYSTEM WITH MOVABLE HEAT EXCHANGER
WO2003059372A3 (en) Combined use of a glp-1 compound and a modulator of diabetic late complications
NO20053041L (no) Behandling av diabetes.
DE602007008385D1 (de) Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris
NZ510920A (en) Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans
WO2003032904A3 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
ATE315558T1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
PT1007055E (pt) Utilizacao de amifostina
WO2005097103A3 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
DK1037629T3 (da) Kombination af et retinsyremetabolismeblokerende middel og en tocopherol
Hodgson et al. Plasma exchange as a source of protein C for acute onset protein C pathway failure
ZA200102727B (en) Method of treating sickle cell disease or thalassemia.
AU2003230830A1 (en) Treatment of type 1 diabetes before and after expression of predisposition markers
PT1267886E (pt) Compostos de vitamina d para o tratamento de nefropatia cronica de alotransplante em pacientes de transplante de rim
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
WO2002017905A3 (en) Treatment of burns